干燥综合征疾病活动度与患者报告结局评估工具的选择
本文讨论原发性干燥综合征(pSS)的评估工具,包括患者报告的ESSPRI和系统表现的ESSDAI,以及眼干和口干的客观测量。近年评估方法的变化和新靶向疗法的出现推动pSS临床试验设计,并首次带来一项阳性随机临床试验。
要点
- pSS评估分患者感知表现(干燥、疼痛、疲劳)和系统表现两个维度。
- ESSPRI评估患者报告结局,ESSDAI评估系统疾病活动度。
- 已有客观测量量化眼干和口干,但少为pSS特异。
核心结论
- pSS的临床特征可分为患者感知表现和系统表现两个维度,需分别使用ESSPRI和ESSDAI进行评估。
- 客观测量可量化眼干和口干的重要性及后果,但少为pSS特异。
- 评估方法的变化和新靶向疗法的出现推动了pSS临床试验设计,并首次带来一项阳性随机临床试验。
研究设计与样本
- 本文为综述,讨论pSS疾病活动度和患者报告结局的评估工具。
主要发现
- 国际协作已开发出共识性临床指数:患者报告结局ESSPRI和系统活动指数ESSDAI。
- 已开发客观测量量化眼干和口干的重要性及后果,但少为pSS特异。
- 正在开发结合上述所有方法的指数。
关键数值与推荐
- ESSPRI用于评估患者报告结局,ESSDAI用于评估系统表现的活动度。
临床怎么用
- 临床评估pSS应同时关注患者感知表现(干燥、疼痛、疲劳)和系统表现。
- 可使用ESSPRI评估患者报告结局,使用ESSDAI评估系统疾病活动度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In primary SS (pSS), clinical features in SS can be divided into two facets: the patient perceived manifestations such as dryness, pain and fatigue, and the systemic manifestations. In the past decades, with efforts made by an international collaboration, consensual clinical indexes were developed for assessing both facets: one patient reported outcome, the EULAR SS Patients Reported Index (ESSPRI), and one activity index for systemic manifestations, the EULAR SS Disease Activity Index (ESSDAI). In addition, objective measures were developed to quantify the importance and consequence of ocular and oral dryness, few being specific of pSS. Work is ongoing to develop indexes combining all these approaches. Recent changes in the assessment of pSS patients, and the emergence of new targeted therapies, have put a greater emphasis on the design of clinical trials in pSS, and led for the first time to a positive randomized clinical trial.
引用
- Seror R, Rauz S, Gosset M, et al. Disease activity and patient reported outcome measures in Sjögren's - what are the best tools to evaluate? Rheumatology (Oxford). 2021. PMID: 31236580. doi:10.1093/rheumatology/kez201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。